

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: a post-hoc analysis of the CREDENCE randomized trial

Authors (Affiliations)

Tae Won Yi, MD (1,2)
Brendan Smyth, PhD (1,3,4)
Gian Luca Di Tanna, PhD (1)
Clare Arnott, PhD (1,5)
Kathryn Cardoza, MD (6)
Amy Kang, MBBS (1,7)
Carol Pollock, MBBS (8,9)
Rajiv Agarwal, MD (10)
George Bakris, MD (11)
David M. Charytan, MD (12)
Dick de Zeeuw, PhD (13)
Hiddo J.L. Heerspink, PhD (1,13)
Bruce Neal, PhD (1,14,15)
David C. Wheeler, MD (16)
Christopher P. Cannon, MD (17)
Hong Zhang, PhD (18)
Bernard Zinman, MDCM (19)
Vlado Perkovic, PhD (1,9)
Adeera Levin, MD (20)
Kenneth W. Mahaffey, MD (21)
Meg Jardine, PhD (1,4,22)
on behalf of the CREDENCE Trial Investigators

Affiliations

1. The George Institute for Global Health, University of New South Wales, Sydney, Australia
2. Department of Medicine, Clinician Investigator Program, University of British Columbia, Vancouver, Canada
3. Department of Renal Medicine, St George Hospital, Kogarah, Australia
4. NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
5. Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, Sydney, New South Wales, Australia
6. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
7. Department of Renal Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia
8. Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia
9. Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia
10. Indiana University School of Medicine and VA Medical Center, Indianapolis, IN, USA

11. Department of Medicine, University of Chicago Medicine, Chicago, IL, USA
12. Nephrology Division, New York University Langone Medical Center, New York University School of Medicine, New York, NY, USA
13. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
14. The Charles Perkins Centre, University of Sydney, Sydney, Australia
15. Imperial College London, London, United Kingdom
16. Department of Renal Medicine, University College London Medical School, London, United Kingdom
17. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
18. Renal Division of Peking University First Hospital, Beijing, China
19. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
20. Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada
21. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
22. Department of Nephrology, Concord Repatriation General Hospital, Sydney, Australia

Corresponding author

Brendan Smyth
Department of Renal Medicine
St George Hospital
50 Montgomery St
Kogarah
NSW 2217
Australia
P: +61 2 9113 2622
E: brendan.smyth@sydney.edu.au

Word Count

Abstract 288/300
Text: 3268/3500

Abstract

Background

It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex. We assessed the effects of canagliflozin according to age and sex in the CREDENCE study.

Study Design

Secondary analysis of a randomized controlled trial.

Setting & Participants

Participants in the CREDENCE trial.

Intervention

Participants were randomly assigned to canagliflozin 100 mg daily or placebo.

Outcomes

Primary composite outcome of kidney failure, doubling of serum creatinine, or death due to kidney or cardiovascular disease. Pre-specified secondary and safety outcomes were also analyzed. Outcomes were evaluated by age at baseline (<60, 60-69, and ≥70 years) and sex in the intention-to-treat population using Cox regression models.

Results

The mean age of the cohort was 63.0±9.2 years and 34% were female. Older age and female sex were independently associated with a lower risk of the composite of adverse kidney outcomes. There was no evidence that the effect of canagliflozin on the primary outcome (a composite of kidney failure, a doubling of the serum creatinine, or death from kidney or cardiovascular causes) differed between age groups (HR 0.67, 95% CI 0.52 to 0.87; HR 0.63, 95% CI 0.48 to 0.82; and HR 0.89, 95% CI 0.61 to 1.29; for the <60, 60-69, and ≥70 year groups, respectively; $P_{\text{interaction}}=0.30$); or among females and males (HR 0.71, 95% CI 0.54 to 0.95; and HR 0.69, 95% CI 0.56 to 0.84, respectively; $P_{\text{interaction}}=0.84$). No differences in safety outcomes by age group or sex were observed.

Limitations

This was a post hoc analysis with multiple comparisons.

Conclusions

Canagliflozin consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age subgroups.

Index words

Diabetic kidney disease; chronic kidney disease; diabetes; kidney outcomes; cardiovascular outcomes; sodium glucose co-transporter 2 inhibitors; canagliflozin; age; sex

Introduction

A personalized approach to treatment is important to ensure therapies are implemented where they will be beneficial, align with patient goals and avoid undue burden or harm.

It is therefore important to know whether the efficacy or safety of a therapy varies between patients with different characteristics, co-morbidities, and baseline risk.

Differences in both age and sex can modify the effect of treatments, reflecting differences in drug-disease interaction for a variety of reasons.^{1,2} For example, modelling of sex differences in the expression of electrolyte transporters in the diabetic kidney suggests the potential for differences in luminal chloride delivery to the macula densa with implications for the natriuretic and intra-renal hemodynamic effects of SGLT2 inhibition and with increasing age comes the accrual of medical comorbidities and changes in pharmacokinetics that may affect drug exposure.³⁻⁵ In addition, different underlying rates of disease progression or adverse event risk can translate into important differences in the absolute balance of risk and benefit, with the potential to influence treatment decisions even when relative risks and benefits remain similar. Although not consistently demonstrated, the risk of progression to kidney failure and the slope of estimated glomerular filtration rate (eGFR) decline may be lower in females with chronic kidney disease (CKD) than in males.⁶⁻⁸ Conversely, CKD and diabetes appear to attenuate the protective effect of female sex on cardiovascular risk.⁹ Similarly, rates of geriatric conditions such as frailty, polypharmacy, cognitive decline, and falls are higher in the elderly with diabetes, which may increase the underlying risk and impact of adverse effects.^{10,11}

SGLT2 inhibitors have now demonstrated benefits in kidney and cardiovascular (CV) outcomes in several large trials, including the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Trial, where canagliflozin effectively lowered the risk of kidney failure, doubling of serum creatinine, and kidney or cardiovascular mortality by 30% in participants with diabetic kidney disease.¹² Various studies demonstrated consistent effect across age and sex, yet these trials primarily focused on primary cardiovascular outcomes, often assessing age groups dichotomized at 65 years, with limited secondary and safety outcomes analyzed.^{13–17} In this secondary analysis of the CREDENCE trial, we investigated whether the effects of canagliflozin on clinically important kidney, CV, and safety outcomes are consistent across age and sex.¹²

Methods

Study Design

The CREDENCE trial methods and statistical analysis have been published previously.¹⁸ The CREDENCE trial was a multi-centre, double-blind, placebo-controlled, randomized trial evaluating the effects of canagliflozin 100mg on kidney, cardiovascular, and safety outcomes in people with T2DM and albuminuric CKD. Key inclusion criteria were age 30 years or older, with a diagnosis of T2DM, an eGFR of 30 to <90 mL/min/1.73m², and urinary albumin-to-creatinine ratio (UACR) >300 to 5000 mg/g. All participants were required to be receiving a stable maximum tolerated dose of angiotensin converting enzyme inhibitor/angiotensin receptor blocker for at least 4

weeks prior to randomization. Randomization was stratified according to the category of eGFR (30 to <45, 45 to <60, 60 to <90 mL/min/1.73m²) at screening.

Study outcomes and participant subgroups

The primary outcome was a composite of kidney failure (defined as dialysis for at least 30 days, kidney transplantation, or an eGFR of <15 mL/min/1.73m² sustained for at least 30 days), doubling of serum creatinine, or death due to kidney or cardiovascular disease. For the present analysis, secondary outcomes were prespecified as the renal composite outcome of end-stage kidney disease, doubling of serum creatinine, or death from renal causes; cardiovascular death; the composite of non-fatal myocardial infarction (MI), stroke, and cardiovascular death; hospitalization for heart failure (HF); and all-cause death. The slope of eGFR decline was an additional secondary outcome. Pre-specified safety outcomes for the present analysis were any adverse event; serious adverse events (all, and those related to study drug); adverse events leading to discontinuation of study medication; fracture; amputation; volume depletion; hypoglycaemia; kidney related adverse events (including acute kidney injury); urinary tract infection; mycotic genital infections; and hospitalisation (all-cause). Efficacy outcomes were determined in the intention-to-treat population; eGFR and safety outcomes were determined in the on-treatment population (i.e. events were considered while the participant was receiving study medication, or within 30 days of ceasing study medication).⁵ As in the primary publication, fracture and amputation were determined in the on-study population (i.e. all events during follow up were considered in participants who had received at least one dose of study medication).¹² Outcomes with fewer than

10 events in each subgroup (canagliflozin and placebo combined) were not analysed. Outcomes were evaluated in subgroups by age (<60, 60-69, and ≥ 70 years) and sex (categorized as female or male per the original study database). A secondary analysis was performed restricted to participants aged 70 years or more, in which those aged 80 years or more were compared to those aged 70-79 years. Given the relatively small size of the cohort aged over 80 years, this analysis was restricted to the primary outcome and selected adverse events (volume depletion, kidney related adverse events, serious adverse events related to study drug, hospitalisation, hypoglycemia, all adverse events, and serious adverse events).

Statistical Analysis

Outcomes were described using the Kaplan-Meier method, and analyzed using proportional subdistribution and Cox proportional hazards models in the presence and absence of competing events, respectively. Models were stratified by screening eGFR. The effect of age and sex on outcomes was assessed in unadjusted models and in adjusted models including both age (as a categorical variable) and sex, with the following potential confounders: race, history of cardiovascular disease, history of heart failure, smoking status, treatment allocation, use of statin, and baseline values of glycated hemoglobin, body mass index, systolic blood pressure, eGFR, urine albumin-to-creatinine ratio (log-transformed), low density lipoprotein-cholesterol, and triglycerides. The proportional hazards assumption was assessed by a formal test on Schoenfeld residuals. A further exploration of change in effect with time was made using a flexible parametric survival (Royston-Parmar) model which allows an estimation

of a time-dependent hazard ratio.¹⁹ The effect of canagliflozin on outcomes was evaluated within subgroups to determine hazard ratios and 95% confidence intervals. The hypothesis that the effects of canagliflozin differed between subgroups (i.e. heterogeneity) was tested by adding the subgroup and a treatment group by subgroup interaction term to the model. The absolute risk difference (and 95% confidence intervals) between canagliflozin and placebo groups was estimated by multiplying the difference in incidence rates (per 1000 patient-years) by 2.5 years (approximating the median duration of the study).²⁰ A p-value of <0.05 was considered significant for main effects, but given the large number of comparisons being made, a p-value for interaction of <0.01 was chosen to reduce the risk of type 1 error.²¹ Analysis was performed using SAS Enterprise Guide version 7.15 (SAS Institute Inc, Cary, USA) and Stata/IC 15.1 (StataCorp LLC, College Station, USA).

Effect modification by age

Heterogeneity by age was explored both as a three-value categorical variable and – to explore the possibility of non-linear differences in treatment effect – by modelling age as a continuous variable using a restricted cubic spline. Knot positions (10th, 50th, and 90th centile) were chosen following the recommendation of Harrell and three knots was chosen as this resulted in the best fit (i.e. lowest Akaike Information Criterion) for the primary outcome in the overall population compared to models using 4, 5, 6 or 7 knots.²² Owing to potential differential risk and cause of death across age groups, a sensitivity analysis was performed accounting for the competing risk of death for key age group analyses.²³

Slope of eGFR decline

Change in eGFR over time was analyzed in the on-treatment population using a multi-slope mixed effects linear spline model with connected slopes from baseline to week 3, and week 3 to study end. The model included fixed effects for screening eGFR strata, baseline eGFR, category of interest (age or sex), trial visit, interaction between category of interest and visit, and interaction between baseline value and visit, along with random intercepts and slopes and assuming an unstructured covariance matrix.

Results

The CREDENCE trial randomized 4401 participants with T2DM and CKD, with a median follow-up duration of 2.62 years. The participants had a mean age of 63 ± 9.2 years. At baseline, 1475 (33.5%), 1854 (42.1%), and 1072 (24.4%) participants were <60, 60-69, and ≥ 70 years, respectively (Table 1). The latter group was comprised predominantly (58.6%) of participants aged 70-74 years (Figure S1). Of the total cohort, 2907 (66.1%) participants were male and 1494 (33.9%) were female (Table 1). The mean baseline eGFR was 56.2 mL/min/1.73m² and median UACR was 927 mg/g. Overall, 585 primary composite outcomes were recorded at a rate of 52.1 per 1000 patient-years.

Outcomes by age

The rate of the primary composite outcome of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death was highest in the <60 years age

group (65.9 per 1000 patient-years) and lower in the 60-69 and ≥ 70 age groups (48.4 and 40.4 per 1000 patient-years, respectively)(Figure 1A). After adjustment for confounding variables, those in the ≥ 70 age group retained a lower risk for the primary outcome (compared to the <60 age group; adjusted hazard ratio [aHR] 0.60, 95% CI 0.47 to 0.77; $P<0.001$)(Table S1). This was driven by lower adjusted estimates for risk of kidney-related components of the primary composite outcome in the ≥ 70 age group (aHR 0.32, 95% CI 0.22 to 0.48; $P<0.001$, and 0.30, 95% CI 0.20 to 0.45; $P<0.001$; for doubling serum creatinine and end-stage kidney disease, respectively)(Table S1). In contrast, adjusted risk of major adverse cardiovascular events, cardiovascular death, hospitalised heart failure, and all-cause death, increased with increasing age (Table S1). The rate of decline in eGFR after week 3 was lowest in the ≥ 70 age group ($2.33\text{ml/min}/1.73\text{m}^2$), followed by the 60-69 age group ($2.88\text{ml/min}/1.73\text{m}^2$) and both were significantly lower than in the <60 age group ($4.24\text{ml/min}/1.73\text{m}^2$; difference from ≥ 70 age group $1.90\text{ml/min}/1.73\text{m}^2$, 95% CI 1.39 to 2.42; from 60-69 age group $1.35\text{ml/min}/1.73\text{m}^2$, 95% CI 0.92 to 1.79; P for both differences <0.001)(Figure 1C). There were no differences in the decline in eGFR to week 3. A sensitivity analysis was performed accounting for the competing risk for death (Table S2) which demonstrated no significant differences from the primary outcome analysis.

Canagliflozin treatment effect by age

Canagliflozin reduced the risk of the primary composite outcome (HR 0.70 [95% CI: 0.59, 0.82]; $P < 0.001$), with no evidence of heterogeneity of treatment effect by age in all participants (HR [95% CI]: 0.67 [0.52-0.87], 0.63 [0.48-0.82], and 0.89 [0.61-1.23] for the <60 , 60-69, and ≥ 70 year groups, respectively)(Figure 2), regardless of whether age

was treated as a categorical or continuous variable (P-interaction=0.30 [Figure 2] and 0.15 [Figure 3], respectively). The proportional hazards assumption was met, although visual inspection of the hazard ratio over time showed a tendency for increased benefit from canagliflozin as follow up time increased (Figure S2). In the overall study population, canagliflozin significantly reduced the risk of the renal composite outcome, doubling of serum creatinine, kidney failure, major adverse cardiovascular events, and hospitalisation for heart failure. Canagliflozin did not significantly reduce the risk of cardiovascular death or all-cause death. No significant differences were detected in the effect within age groups for these outcomes, including when age was analyzed as a continuous variable (Figure 2 and 3). These conclusions did not differ when death was treated as a competing risk, nor when time-dependent hazards were modelled (Figure S3). In the very elderly, there were 8 primary outcomes in participants aged 80 years or more at baseline (2 events in the canagliflozin group and 6 events in the placebo group) (Table S3). The absolute reduction in event rates were most prominent in the younger cohort, consistent with their higher baseline risk of kidney events compared to older participants. With the exception of heart failure, the absolute reduction in event rates was attenuated in those aged over 70 years (Figure 2).

Outcomes by Sex

The rates of the primary composite outcome were similar in males and females (52.7 and 51.0 per 1000 patient-years)(Figure 1B). Females had a lower risk of the primary composite outcome after adjustment for confounding variables (aHR 0.82, 95% CI 0.68 to 0.98, P=0.03)(Table S4). Similarly, the adjusted risks of the components of the primary composite outcome tended to be lower in females, although this did not reach

statistical significance for all outcomes (Table S4). The slope of eGFR decline after week 3 did not differ between sexes (female 3.28ml/min/1.73m² vs. male 3.14ml/min/1.73m²; difference 0.14ml/min/1.73m², 95% CI 0.26 to 0.54; P=0.48) (Figure 1D). There was no difference in decline in eGFR to week 3.

Canagliflozin treatment effect by sex

There was no evidence that the effects of canagliflozin on the primary composite outcome and secondary outcomes differed by sex (HR [95% CI]: 0.71 [0.54-0.95] and 0.69 [0.56-0.84] for female and male, respectively; P-interaction 0.84) (Figure 4). The proportional hazards assumption was met. Visual inspection of the hazard ratio over time showed a tendency for increased benefit from canagliflozin as follow up time increased in females, with little apparent change in hazard ratio over time in males (Figure S2). There was no evidence that sex modified the effect of canagliflozin across age group categories for any of the tested outcomes (Table S4) and absolute difference in risk with canagliflozin was similar between sexes (Figure 4).

Safety Outcomes

The effect of canagliflozin on safety outcomes was consistent among age groups and by sex (Tables 2 and 3). Although the absolute number of events were low, there was no evidence that those aged 80 years or more were at greater risk of adverse events from canagliflozin than their counterparts aged 70-79, with similar rates of volume depletion, kidney related adverse events, hospitalisation, serious adverse events related to study drug, hypoglycemia, all adverse events, and serious adverse events (Table S3). Only two serious adverse events related to study drug occurred in participants aged 80 years or more at baseline, 1 in the canagliflozin and one in placebo. While the

absolute incidence of mycotic genital infections was higher in females than in males allocated to canagliflozin (12.9 vs. 8.5 per 1000 patient years), the relative increase in risk for genital infections tended to be higher in males (HR 9.30 vs. 2.10 in males and females) (Table 3) owing to low risk in the placebo group, although this difference did not reach significance against the pre-specified interaction threshold. No heterogeneity was observed with canagliflozin on fracture and urinary tract infection (P-interaction = 0.011, P-interaction = 0.035, respectively).

Discussion

In this secondary analysis of the CREDENCE trial, the effects of canagliflozin on kidney and cardiovascular events were consistent across age groups and sex. This builds on the previously reported consistency of canagliflozin on the primary composite and MACE endpoints between sex and age groups (<65 and ≥65 years).^{12,24} There was no evidence that any subgroup, defined by age or sex, were at proportionally higher risk of a serious adverse event from canagliflozin treatment. This is the first report confirming that the benefits of SGLT2 inhibitors on kidney outcomes are preserved across age in a high-risk population with albuminuric chronic kidney disease and T2DM, and follows analyses of previous cardiovascular and heart failure outcome trials, which have demonstrated consistent efficacy among older participants.^{17,25–27}

While the relative benefits of canagliflozin were consistent across age groups, the lower risk of kidney events (even after adjustment for baseline differences) and lower eGFR slope in those aged over 70 years translated into a reduced absolute benefit. For example, the number needed to treat for those aged 70 and over to prevent

one primary event was 90, compared to 17 for those aged under 60 years. In contrast, a subgroup analysis of the CANVAS trial, demonstrated greater impact on kidney outcomes with canagliflozin in those aged over 65 years, however, the baseline kidney risk in the CANVAS cohort was substantially lower than that of the CREDENCE population.²⁸ Yet both observations are tempered, not just by the post-hoc nature of the analyses, but also by the potential limitations in generalising older patients enrolled in randomized studies to the general older population with diabetic kidney disease. The tendency for randomised trial cohorts to exclude older and frailer patients, is well known, and the generalisability (measured as proportion of patients eligible) of previous SGLT2 inhibitor trials to the general population with T2DM varies from 17-59%.^{29–31} Observational studies have found variable associations between age and rate of decline in kidney function in the general population.^{32–34} In populations referred to nephrology services, increasing age has been independently associated with a lower risk of doubling of serum creatinine and a slower decline in eGFR.^{35–37} A higher prevalence of low- to moderately proteinuric vascular nephropathy in older CKD cohorts may contribute to this finding, as is suggested by the lower median albuminuria in patients aged >70 in the present study.³⁷ Fundamentally, a greater individual benefit (in terms of reduced decline in kidney function) from SGLT2 inhibitor therapy will, assuming consistent relative effects, accrue to those at greatest underlying risk of disease progression. While the present study provides no evidence to suggest that age affects the relative benefit of SGLT2 inhibitor therapy, it does suggest that the absolute benefit may be greatest in younger patients with diabetic kidney disease.

The evidence for a difference in risk of kidney disease by sex in those with T2DM is inconsistent, with prior studies showing evidence for a higher risk in males, higher risk in females or no difference between sexes.⁶ Nevertheless, the present results show clear evidence that the beneficial effects of canagliflozin on both kidney and cardiovascular endpoints are similar in males and females. This is consistent with previously published secondary and pooled analyses examining cardiovascular efficacy of SGLT2 inhibitors.^{21,38,39}

Canagliflozin demonstrated adverse effects consistent with the SGLT2 inhibitor class.²⁵ Although the absolute number of mycotic infections was higher in females than males, the present study and pooled analyses of previous trials have noted numerically greater relative risks in males. This reflects low baseline risk in males and in neither analysis did this interaction attain significance adjusted for multiple comparisons.²¹ The consistency in rates of adverse effects across age groups is in keeping with other reports from major cardiovascular outcome SGLT2 inhibitor trials.^{21,27} Observational studies in elderly patients have largely found SGLT2 inhibitors are well tolerated in older patients.^{40,41} Although we also found no evidence that the efficacy of canagliflozin on the primary study endpoint, or the safety of this drug, was diminished in those aged 80 years or more, it is important to emphasize the limited number of participants in this age group. Dedicated studies that enrol the very elderly are required to properly determine the safety and efficacy of SGLT2 inhibitors in this vulnerable population.

The strengths of the present analysis include the ability to assess the effects of age and sex in a large trial of high-risk patients with albuminuria and reduced kidney function. The results were robust with similar results regardless of whether age was

categorized or continuous. Nevertheless, the findings from this post-hoc analysis should be interpreted in light of some limitations. First, the CREDENCE trial was not powered to detect differences in treatment effect by age or sex, a limitation compounded by the fact that the trial was stopped early due to efficacy for the primary endpoint. Secondly, we deliberately reduced the significance threshold to account for the risk of type 1 error with the multiple comparisons being made in this post-hoc analysis which may reduce the sensitivity to detect smaller differences between groups. There were relatively few females, black participants, and low numbers of patients at the extremes of age in the study which may limit the generalizability of these findings to these populations.

In conclusion, the CREDENCE data suggests that canagliflozin consistently improves kidney and cardiovascular outcomes with little variation in risk of adverse events in patients with type 2 diabetes and albuminuric chronic kidney disease across a broad range of ages and in both males and females. The absolute benefit of canagliflozin was greater in younger participants who were at higher risk of adverse kidney outcomes. These findings should help to clarify decision making for those with diabetes and chronic kidney disease.

Acknowledgements

We thank the participants in this trial and thank the study investigators, who are listed in the Supplementary Appendix to the primary CREDENCE study publication. TWY is supported by the Clinician Investigator Program at the University of British Columbia. BS is supported by a Jacquot Research Establishment Fellowship from the Royal Australasian College of Physicians.

Disclosures

The CREDENCE study was sponsored by Janssen Research and Development, and was conducted collaboratively by the sponsor, an academic-led steering committee, and an academic research organization, George Clinical. This post hoc analysis of the CREDENCE trial was not specifically funded. The funders were not involved in the design, analysis, reporting, or decision to submit this manuscript for publication. BS is supported by The Jacquot Research Establishment Fellowship from the Royal Australasian College of Physicians. CA reports grants from MRFF Priority Investigator Grant, NSW Health EMCR Grant, and honoraria from Amgen. AK is supported by an NHMRC Postgraduate Scholarship (1150349) via the University of New South Wales, an Australian Government Research Training Program Fee Offset and has received a George Institute Scholarship. CP reports consulting fees for study advisory board and travel support from Janssen. RA reports research funding from NIH and VA, royalties from UpToDate, consulting fees from Akebia, Bayer, Boehringer Ingelheim, Diamedica, Merck, Reata, Relypsa, Lexicon. He reports honoraria from Medscape, Cardiometabolic Health, various Universities, and consulting fees for advisory board positions from Akebia, Bayer, Relypsa, Sanofi, Chinook, and AstraZeneca. He is associate editor for Nephrology Dialysis and Transplantation, and for the American Journal of Nephrology. GB reports consulting fees for advisory board positions for Bayer, Vascular Dynamics, Quantum, Genomics, Janssen, Alnylam, and Novo Nordisk. He has received consulting fees from Merck, Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, and Novo Nordisk. He has received travel support from Novo Nordisk, Merck, Astra Zeneca, Quantum Genomics, Ionis, and Alnylam. He sits on an advisory board for the NIH RO1 study. DMC reports personal fees from Janssen during the conduct of the study, consulting for Eli Lilly/Boehringer Ingelheim, Janssen (steering committee), PLC medical (clinical events committee), Astra Zeneca, Allena Pharmaceuticals (DSMB), Fresenius, Amgen, Gilead, Novo Nordisk, GSK, Medtronic, Merck, Amgen, CSL Behring, Zogenix, Renalytix; and research funding from Medtronic-clinical trial support; Bioporto-clinical trial support; Gilead; NovoNordisk; Amgen; and advisory or leadership role to CJASN; and expert witness fees related to proton pump inhibitors. DdZ reports serving on advisory boards and/or as a speaker for Bayer,

Boehringer Ingelheim, Fresenius, Travers Pharmaceuticals and Mitsubishi Tanabe; serving on steering committees and/or as a speaker for AbbVie and Janssen; and serving on data safety and monitoring committees for Bayer. HJLH reports grants from AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and consulting fees from AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, NovoNordisk, Janssen, Travers Pharmaceuticals. BN has received funding for conduct of CREDENCE study from Janssen, and consulting fees for advisory board positions for Janssen and Mitsubishi Tanabe Pharma. All fees were paid to institution. DCW has received fees and travel funding from Janssen for his role as a member of the CREDENCE steering committee. He has also received fees for advisory boards, steering committee roles, or scientific presentations from Amgen, AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Mundipharma, Merck Sharp & Dohme, Napp, Tricida, Vifor and Zydus. CPC reports research grants from Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Novo Nordisk, Pfizer, and consulting fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, Sanofi. He serves on the DSMB for the Veteran's Administration, Applied Therapeutics and NovoNordisk. HZ reports consulting fees from Janssen. BZ reports consulting fees from Janssen. VP reports support for the CREDENCE trial as the chair of the Steering Committee from Janssen, and consulting fee from AbbVie, Bayer, Boehringer Ingelheim, Chinook, GlaxoSmithKline, Janssen, Pfizer; Astellas, AstraZeneca, Baxter, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pharmalink, Relypsa, Retrophin, Roche, Sanofi, Servier, and Vitae; honoraria from AbbVie, Bayer, Boehringer Ingelheim, Chinook, GlaxoSmithKline, Janssen, and Pfizer; Astellas, AstraZeneca, Bayer, Baxter, Bristol-Myers Squibb, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pharmalink, Relypsa, Retrophin, Roche, Sanofi, Servier, and Vitae. AL was a member of the Steering committee for CREDENCE and has received grant support from Janssen. KWM has received research support from AHA, Apple, Inc, Bayer,

California Institute Regenerative Medicine, Eidos, Ferring, Gilead, Google (Verily), Idorsia, Johnson & Johnson, Luitpold, PAC-12, Precordior, Sanifit; consulting fees from Amgen, Applied Therapeutics, AstraZeneca, Bayer, CSL Behring, Elsevier, Fibrogen, Inova, Johnson & Johnson, Lexicon, Myokardia, Novartis, Novo Nordisk, Otsuka, Phasebio, Portola, Precordior, Quidel, Sanofi, Theravance, and honoraria from Inova, Intermountain Health, Medscape, Mount Sinai, CSL Behring. MJJ is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, and MSD; has received Advisory, Steering Committee and/or speaker fees from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Cestas Lynx, Chinook, Medscape, CSL, Janssen, MSD, Roche and Vifor; with any consultancy, honoraria or travel support paid to her institution.

REFERENCES

1. Bartz D, Chitnis T, Kaiser UB, et al. Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review. *JAMA Intern Med*. 2020;180(4):574-583. doi:10.1001/jamainternmed.2019.7194
2. Soldin O, Mattison D. Sex Differences in Pharmacokinetics and Pharmacodynamics. *Clin Pharmacokinet*. 2009;48(3):143-157. doi:10.2165/00003088-200948030-00001
3. Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. *Clin Pract (Lond)*. 2014;11(5):525-535. doi:10.2217/cpr.14.46
4. Swapnasrita S, Carlier A, Layton AT. Sex-Specific Computational Models of Kidney Function in Patients With Diabetes. *Front Physiol*. 2022;13:741121. doi:10.3389/fphys.2022.741121
5. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *Br J Clin Pharmacol*. 2004;57(1):6-14. doi:10.1046/j.1365-2125.2003.02007.x
6. Maric-Bilkan C. Sex Differences in Diabetic Kidney Disease. *Mayo Clinic Proceedings*. 2020;95(3):587-599. doi:10.1016/j.mayocp.2019.08.026
7. Ricardo AC, Yang W, Sha D, et al. Sex-Related Disparities in CKD Progression. *J Am Soc Nephrol*. 2019;30(1):137-146. doi:10.1681/ASN.2018030296
8. Minutolo R, Gabbai FB, Chiodini P, et al. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies. *Am J Kidney Dis*. 2020;75(1):30-38. doi:10.1053/j.ajkd.2019.05.019
9. Toth-Manikowski SM, Yang W, Appel L, et al. Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study. *Am J Kidney Dis*. 2021;78(2):200-209.e1. doi:10.1053/j.ajkd.2021.01.020
10. Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. *Diabetes Obes Metab*. 2014;16(12):1192-1203. doi:https://doi.org/10.1111/dom.12362
11. Association AD. 12. Older Adults: Standards of Medical Care in Diabetes—2020. *Diabetes Care*. 2020;43(Supplement 1):S152-S162. doi:10.2337/dc20-S012
12. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *New England Journal of Medicine*. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744

13. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
14. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
15. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389
16. Butt JH, Docherty KF, Petrie MC, et al. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. *JAMA Cardiology*. 2021;6(6):678-689. doi:10.1001/jamacardio.2021.0379
17. Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. *Circulation*. 2020;141(2):100-111. doi:10.1161/CIRCULATIONAHA.119.044133
18. Jardine MJ, Mahaffey KW, Neal B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. *Am J Nephrol*. 2018;46(6):462-472. doi:10.1159/000484633
19. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. *Stat Med*. 2002;21(15):2175-2197. doi:10.1002/sim.1203
20. Arnott C, Li JW, Cannon CP, et al. THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL. *Journal of the American College of Cardiology*. 2020;75(11, Supplement 1):674. doi:10.1016/S0735-1097(20)31301-2
21. Rådholm K, Zhou Z, Clemens K, Neal B, Woodward M. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. *Diabetes Obes Metab*. 2020;22(2):263-266. doi:10.1111/dom.13876
22. Harrell FE. *Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis*. Springer New York; 2010.
23. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association*. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144

24. Mahaffey KW, Jardine MJ, Bompont S, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. *Circulation*. 2019;140(9):739-750. doi:10.1161/CIRCULATIONAHA.119.042007
25. Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. *J Am Geriatr Soc*. 2016;64(3):543-552. doi:10.1111/jgs.14028
26. Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. *Age and Ageing*. 2019;48(6):859-866. doi:10.1093/ageing/afz096
27. Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study. *Dia Care*. 2020;43(2):468-475. doi:10.2337/dc19-1476
28. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol*. 2018;6(9):691-704. doi:10.1016/S2213-8587(18)30141-4
29. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials*. 2015;16(1):495. doi:10.1186/s13063-015-1023-4
30. Smyth B, Haber A, Trongtrakul K, et al. Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease. *JAMA Intern Med*. 2019;179(10):1316-1324. doi:10.1001/jamainternmed.2019.1501
31. Birkeland KI, Bodegard J, Norhammar A, et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. *Diabetes Obes Metab*. 2019;21(4):968-974. doi:10.1111/dom.13612
32. Young BA, Katz R, Boulware LE, et al. Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). *Am J Kidney Dis*. 2016;68(2):229-239. doi:10.1053/j.ajkd.2016.02.046
33. Waas T, Schulz A, Lotz J, et al. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. *Sci Rep*. 2021;11(1):10165. doi:10.1038/s41598-021-89442-7
34. Toyama T, Kitagawa K, Oshima M, et al. Age differences in the relationships between risk factors and loss of kidney function: a general population cohort study. *BMC Nephrol*. 2020;21(1):477. doi:10.1186/s12882-020-02121-z

35. Anderson AH, Xie D, Wang X, et al. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *Am J Kidney Dis*. 2021;77(1):56-73.e1. doi:10.1053/j.ajkd.2020.07.011
36. Chesnaye NC, Dekker FW, Evans M, et al. Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study. *Nephrol Dial Transplant*. 2020;36(9):1656-1663. doi:10.1093/ndt/gfaa095
37. Rosansky SJ, Schell J, Shega J, et al. Treatment decisions for older adults with advanced chronic kidney disease. *BMC Nephrology*. 2017;18(1):200. doi:10.1186/s12882-017-0617-3
38. Rådholm K, Wu JH, Wong MG, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. *Diabetes Research and Clinical Practice*. 2018;140:118-128. doi:10.1016/j.diabres.2018.03.027
39. Zinman B, Inzucchi SE, Wanner C, et al. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. *Diabetologia*. 2018;61(7):1522-1527. doi:10.1007/s00125-018-4630-2
40. Abdelhafiz AH, Sinclair AJ. Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. *Journal of Diabetes*. 2020;34(9):107639. doi:10.1016/j.jdiacomp.2020.107639
41. Iskander C, Cherney DZ, Clemens KK, et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. *CMAJ Canadian Medical Association Journal*. 2020;192(14):E351-E360. doi:10.1503/cmaj.191283

Data Statement

Data from this study is available in the public domain via the Yale University Open Data Access Project (<http://yoda.yale.edu/>). This includes deidentified individual participant data, data definition specification, annotated case report form, protocol with amendments and primary statistical analysis plan.

Table 1: Baseline characteristics by age group and sex

Data are mean±standard deviation or number (%), unless otherwise specified.

	Age group			Sex		All
	<60	60-69	≥70	Female	Male	
N	1475	1854	1072	1494	2907	4401
Age (Years)	52.7±5.5	64.7±2.8	74.3±3.6	62.9±9.2	63.1±9.2	63.0±9.2
Female sex (%)	503 (34)	632 (42)	359 (24)	1494 (100)	0.0 (0.0)	1494 (34)
Race (%)						
White	861 (58)	1283 (69)	787 (73)	992 (66)	1939 (67)	2931 (67)
Black	105 (7)	70 (4)	49 (5)	102 (7)	122 (4)	224 (5)
Asian	374 (25)	346 (19)	157 (15)	245 (16)	632 (22)	877 (20)
Other	135 (9)	155 (8)	79 (7)	155 (10)	214 (7)	369 (8)
Current smoker (%)	265 (18)	262 (14)	112 (10)	133 (9)	506 (17)	639 (15)
Hypertension (%)	1402 (95)	1805 (97)	1053 (98)	1449 (97)	2811 (97)	4260 (97)
Heart failure (%)	161 (11)	309 (17)	182 (17)	257 (17)	395 (14)	652 (15)
Diabetes duration (years)	13.7±7.4	15.9 ±8.2	18.4 ±10.1	16.2±8.6	15.6±8.6	15.8±8.6
Cardiovascular disease (%)	589 (40)	986 (53)	645 (60)	695 (47)	1525 (53)	2220 (50)
Amputation (%)	98 (7)	97 (5)	39 (4)	51 (3)	183 (6)	234 (5)
BMI (kg/m ²)	31.9±6.7	31.5 ±6.2	30.2 ±5.2	31.9±6.8	31.0±5.8	31.3±6.2
Blood pressure (mmHg)						
Systolic	137.9±15.4	140.4±15.5	142.1 ±15.7	140.2±15.8	139.9±15.5	140±15.6
Diastolic	80.7±8.7	78.0±9.3	75.5 ±9.5	77.5±9.1	78.7±9.5	78.3±9.4
Hemoglobin A1c (%)	8.5±1.4	8.2±1.3	8.0±1.2	8.5±1.4	8.1±1.2	8.3±1.3
eGFR (mL/min/1.73m ²)	58.8±19.4	56.3±17.6	52.3 ±16.9	56.4±18.4	56.1±18.2	56.2±18.2
UACR (mg/g)	1108 (511-2337)	876.5 (473-1724)	742.5 (418-1493.5)	984 (460-1954)	888 (465-1776)	927 (463-1833)

Table 2: Adverse events by age group

Hazard ratios and interactions from Cox proportional hazards regression. CI, confidence interval; HR, hazard ratio. Sensitivity analyses treating age as a continuous variable result in similar findings.

Hazard ratio: Canagliflozin compared with placebo, treating age as a continuous variable (result in similar findings).							
	n/N		Event rate		HR (95% CI)	P-value	P-interaction
	Canagliflozin	Placebo	Canagliflozin	Placebo			
Fracture							
<60	17/731	9/744	9.1	4.7	1.92 (0.86 to 4.31)	0.11	0.15
60-69	28/950	35/904	11.3	15.2	0.75 (0.46 to 1.24)	0.26	
70+	22/521	24/551	16.3	17.0	0.95 (0.53 to 1.69)	0.86	
Amputation							
<60	28/731	30/744	15.2	15.9	0.95 (0.57 to 1.59)	0.85	0.77
60-69	33/950	25/904	13.4	10.8	1.23 (0.73 to 2.07)	0.43	
70+	9/521	8/551	6.6	5.6	1.20 (0.46 to 3.11)	0.71	
Volume depletion							
<60	43/731	33/744	26.8	20.8	1.30 (0.83 to 2.05)	0.26	0.67
60-69	56/950	38/903	26.2	19.0	1.42 (0.94 to 2.14)	0.10	
70+	45/519	44/550	40.1	37.7	1.11 (0.73 to 1.69)	0.61	
Hypoglycaemia							
<60	77/731	73/744	50.4	48.3	1.06 (0.77 to 1.46)	0.71	0.38
60-69	98/950	99/903	47.1	52.2	0.93 (0.70 to 1.23)	0.60	
70+	50/519	68/550	45.3	61.3	0.75 (0.52 to 1.08)	0.12	
Kidney related events, including AKI							
<60	116/731	155/744	73.9	101.5	0.71 (0.56 to 0.90)	0.005	0.99
60-69	113/950	145/903	53.2	74.4	0.71 (0.56 to 0.91)	0.006	
70+	61/519	88/550	54.4	77.0	0.70 (0.50 to 0.96)	0.03	
Urinary tract infection							
<60	80/731	60/744	51.1	38.8	1.32 (0.94 to 1.84)	0.11	0.24
60-69	92/950	94/903	43.6	48.8	0.91 (0.68 to 1.21)	0.51	
70+	73/519	67/550	66.3	58.8	1.12 (0.80 to 1.56)	0.52	
Hospitalisation							
<60	218/731	248/744	138.1	155.7	0.89 (0.74 to 1.07)	0.20	0.44
60-69	314/950	349/904	153.3	186.4	0.83 (0.71 to 0.97)	0.02	
70+	202/521	214/551	182.5	186.0	0.96 (0.79 to 1.17)	0.70	
Mycotic genital infections							
<60	14/731	6/744	8.5	3.4	2.38 (0.91 to 6.19)	0.08	0.33
60-69	24/950	3/903	11.0	1.5	7.56 (2.28 to 25.11)	0.001	
70+	12/519	4/550	10.3	3.3	3.11 (1.00 to 9.64)	0.05	
All adverse events							
<60	598/731	632/744	926.1	1103.7	0.88 (0.79 to 0.99)	0.031	0.95
60-69	766/950	767/903	885.5	1095.3	0.87 (0.79 to 0.97)	0.009	
70+	420/519	461/550	858.0	1050.7	0.85 (0.74 to 0.97)	0.017	
Serious adverse events							
<60	215/731	237/744	148.5	168.5	0.89 (0.74 to 1.07)	0.20	0.23
60-69	312/950	352/903	165.8	207.9	0.81 (0.69 to 0.94)	0.005	
70+	210/519	217/550	216.5	214.3	1.00 (0.82 to 1.20)	0.96	
Serious adverse events related to study drug							
<60	15/731	16/744	9.1	9.9	0.91 (0.45 to 1.85)	0.80	0.31
60-69	26/950	13/903	11.8	6.4	1.87 (0.96 to 3.65)	0.06	
70+	21/519	13/550	18.0	10.7	1.69 (0.84 to 3.38)	0.14	

Adverse events leading to drug withdrawal							
<60	88/731	90/744	53.4	55.5	0.95 (0.71 to 1.28)	0.75	0.77
60-69	111/950	122/903	50.3	60.1	0.83 (0.64 to 1.07)	0.14	
70+	68/519	74/550	57.7	61.4	0.94 (0.67 to 1.31)	0.70	

Table 3: Adverse events by sex

Hazard ratios and interactions from Cox proportional hazards regression. CI, confidence interval; HR, hazard ratio.

	n/N		Event rate		HR (95% CI)	P-value	P-interaction
	Canagliflozin	Placebo	Canagliflozin	Placebo			
Fracture							
Female	29/762	43/732	15.0	23.5	0.64 (0.40 to 1.02)	0.06	0.011
Male	38/1440	25/1467	10.1	6.6	1.55 (0.93 to 2.56)	0.09	
Amputation							
Female	15/762	13/732	7.7	6.9	1.11 (0.53 to 2.33)	0.79	0.99
Male	55/1440	50/1467	14.7	13.3	1.11 (0.76 to 1.63)	0.58	
Volume depletion							
Female	49/761	35/731	29.3	22.0	1.32 (0.86 to 2.04)	0.21	0.72
Male	95/1439	80/1466	29.8	25.3	1.20 (0.89 to 1.62)	0.22	
Hypoglycaemia							
Female	107/761	97/731	68.3	65.9	1.04 (0.79 to 1.37)	0.76	0.22
Male	118/1439	143/1466	37.5	47.0	0.83 (0.65 to 1.06)	0.14	
Kidney related events, including AKI							
Female	93/761	115/731	55.6	74.6	0.72 (0.55 to 0.95)	0.02	0.81
Male	197/1439	273/1466	62.7	88.7	0.70 (0.58 to 0.84)	0.0001	
Urinary tract infection							
Female	170/761	130/731	110.6	89.7	1.23 (0.98 to 1.54)	0.08	0.035
Male	75/1439	91/1466	23.2	28.7	0.82 (0.6 to 1.11)	0.19	
Hospitalisation							
Female	236/762	244/732	144.8	155.0	0.92 (0.77 to 1.10)	0.35	0.56
Male	498/1440	567/1467	160.4	186.4	0.86 (0.77 to 0.97)	0.017	
Mycotic genital infections							
Female	22/761	10/731	12.6	6.1	2.10 (1.00 to 4.45)	0.05	0.038
Male	28/1439	3/1466	8.4	0.9	9.30 (2.83 to 30.60)	0.0002	
All adverse events							
Female	632/761	623/731	975.3	1143.2	0.89 (0.80 to 1.00)	0.043	0.70
Male	1152/1439	1237/1466	851.9	1060.2	0.86 (0.80 to 0.93)	0.0003	
Serious adverse events							
Female	246/761	243/731	163.9	173.2	0.94 (0.78 to 1.12)	0.47	0.34
Male	491/1439	563/1466	175.5	207.9	0.84 (0.75 to 0.95)	0.006	
Serious adverse events related to study drug							
Female	20/761	14/731	11.6	8.6	1.32 (0.67 to 2.61)	0.43	0.76
Male	42/1439	28/1466	12.8	8.6	1.51 (0.94 to 2.44)	0.09	
Adverse events leading to drug withdrawal							
Female	78/761	93/731	45.0	57.8	0.76 (0.57 to 1.03)	0.08	0.21
Male	189/1439	193/1466	57.3	59.5	0.97 (0.79 to 1.19)	0.76	

Summary of figures

Figure 1: Time to occurrence of primary outcome and eGFR slope by age and sex.

A. Primary outcome Kaplan-Meier curves by age group. B. Primary outcome Kaplan-Meier curves by sex. C. eGFR slope by age group. D. eGFR slope by sex.

Analyses include participants in both canagliflozin and placebo groups. Hazard ratios are not adjusted for confounding variables (see text for adjusted HRs). Primary outcome comprises doubling of serum creatinine, kidney failure (dialysis, transplantation, or eGFR < 15ml/min/1.73m²), cardiovascular or renal death.

Figure 2: Effect of canagliflozin on primary and secondary outcomes by age.

Relative effect of canagliflozin and absolute difference in events per 1000 patients over 2.5 years.

Figure 3: Effect of canagliflozin on main outcomes by age, treating age as continuous variable.

Hazard ratio from Cox proportional hazards regression with age treated as restricted cubic spline variable.

Owing to wide confidence intervals at the extremes of the study population age range, figures have been truncated to the 5th to 95th centiles of age.

Figure 4: Effect of canagliflozin on primary and secondary outcomes by sex.

Relative effect of canagliflozin and absolute difference in events per 1000 patients over 2.5 years.